Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

674.75INR
23 Jan 2015
Change (% chg)

Rs20.60 (+3.15%)
Prev Close
Rs654.15
Open
Rs656.00
Day's High
Rs684.45
Day's Low
Rs655.00
Volume
300,100
Avg. Vol
163,732
52-wk High
Rs684.45
52-wk Low
Rs366.70

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.50
Market Cap(Mil.): Rs544,099.69
Shares Outstanding(Mil.): 802.92
Dividend: 2.00
Yield (%): 0.30

Financials

  CIPL.BO Industry Sector
P/E (TTM): 47.89 40.21 40.82
EPS (TTM): 14.15 -- --
ROI: 11.02 19.07 18.35
ROE: 11.10 19.85 19.25
Search Stocks

Delhi High Court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - The Delhi High Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

UPDATE 1-India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI, Jan 13 - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI, Jan 13 - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

Aspen, Cipla win share of $860 million South Africa AIDS drug tender

JOHANNESBURG - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

24 Dec 2014

Aspen, Cipla win share of $860 million S.Africa AIDS drug tender

JOHANNESBURG - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

24 Dec 2014

UPDATE 1-Aspen, Cipla win share of $860 mln S.Africa AIDS drug tender

JOHANNESBURG, Dec 24 - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

24 Dec 2014

Aspen, Cipla among winners in $860 mln S.Africa aids drug tender

JOHANNESBURG, Dec 24 - South Africa's National Health Department said on Wednesday it has awarded a 10 billion rand ($860 million) tender to four pharmaceutical firms to supply AIDS treatment drugs.

24 Dec 2014

Novartis sues Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

Earnings vs. Estimates

Search Stocks